Department of Oral Pathology, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.
Surgeon. 2013 Jun;11(3):147-52. doi: 10.1016/j.surge.2012.07.004. Epub 2012 Aug 9.
Microvessel density (MVD) can be used for determining neoplastic neovascularisation. Tumour angiogenesis correlates with prognosis of cancers in many organs. The aims of this study were to evaluate MVD as demonstrated by CD31 and CD105 in salivary gland tumours (SGTs), and to correlate the MVD results with clinicopathological characteristics of the tumours.
Using a retrospective cohort study design, we enrolled SGTs patients at the Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand, over the 22-year period. The predictor variables included demographic, anatomic and histopathological parameters. The outcome measure was average CD31-MVD and CD105-MVD counted by the "hot spot" method. Descriptive, uni- and bivariate statistics were computed, and P <0.05 was considered statistically significant.
The study sample consisted of 43 subjects with a mean age of 39.6 ± 17.8 years (range, 9-82), including 26 females (60.5%), diagnosed with SGTs. In this cohort, 58.1% of the cases were benign, and 83.7% were minor SGTs. There was a significant correlation between CD31-MVD and CD105-MVD (r = 0.8, P < 0.001), but mean CD31-MVD and CD105-MVD were 17.7 ± 9.3 and 12.8 ± 7.4, respectively (P = 0.009). Age, gender and tumour site were not individually associated with significant differences between CD31-MVD and CD105-MVD. Tumours with myoepithelial cells had lower MVD than those without myoepithelial cells (P = 0.04 for CD31; P = 0.03 for CD105). Only CD105-MVD showed statistical difference between benign and malignant SGTs (P = 0.01).
These results suggest that MVD in SGTs can be demonstrated by CD31 and CD105. Despite a strong correlation, CD31-MVD is always higher than CD105-MVD and cannot differentiate between benign and malignant SGTs. The presence of myoepithelial cells within SGTs affects the MVD analysis using either CD31 or CD105, while age, gender and tumour location do not.
微血管密度 (MVD) 可用于确定肿瘤新生血管生成。肿瘤血管生成与许多器官癌症的预后相关。本研究的目的是评估 CD31 和 CD105 在唾液腺肿瘤 (SGT) 中的 MVD,并将 MVD 结果与肿瘤的临床病理特征相关联。
使用回顾性队列研究设计,我们招募了泰国朱拉隆功大学牙科学院的 SGT 患者,时间跨度为 22 年。预测变量包括人口统计学、解剖学和组织病理学参数。观察指标为通过“热点”法计算的平均 CD31-MVD 和 CD105-MVD。计算了描述性、单变量和双变量统计数据,P <0.05 被认为具有统计学意义。
研究样本包括 43 名平均年龄为 39.6 ± 17.8 岁(范围 9-82 岁)的患者,其中 26 名女性(60.5%),诊断为 SGT。在该队列中,58.1%的病例为良性,83.7%为小唾液腺肿瘤。CD31-MVD 与 CD105-MVD 之间存在显著相关性(r = 0.8,P < 0.001),但平均 CD31-MVD 和 CD105-MVD 分别为 17.7 ± 9.3 和 12.8 ± 7.4(P = 0.009)。年龄、性别和肿瘤部位与 CD31-MVD 和 CD105-MVD 之间的差异无显著相关性。有肌上皮细胞的肿瘤 MVD 低于无肌上皮细胞的肿瘤(CD31:P = 0.04;CD105:P = 0.03)。仅 CD105-MVD 在良性和恶性 SGT 之间显示出统计学差异(P = 0.01)。
这些结果表明,CD31 和 CD105 可在 SGT 中显示 MVD。尽管存在很强的相关性,但 CD31-MVD 始终高于 CD105-MVD,并且不能区分良性和恶性 SGT。SGT 中肌上皮细胞的存在会影响使用 CD31 或 CD105 进行的 MVD 分析,而年龄、性别和肿瘤位置则不会。